Nibec Co., Ltd. (138610) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Nibec Co., Ltd. (138610:KRX), powered by AI.

Current Price
₩23,750
P/E Ratio
58.2
Market Cap
270.0B
Sector
Healthcare
What is the Nibec Co., Ltd. stock price forecast?

Nibec Co., Ltd. is currently trading at ₩23,750. View real-time AI analysis on Alpha Lenz.

What is Nibec Co., Ltd. insider trading activity?

View the latest insider trading data for Nibec Co., Ltd. on Alpha Lenz.

What is Nibec Co., Ltd.'s P/E ratio?

Nibec Co., Ltd.'s P/E ratio is 58.2.

Nibec Co., Ltd.

KRX · 138610
₩23,750-650(-2.66%)Market closedKRX regular session 09:00–15:30 KST
Ask about Nibec Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Nibec Co., Ltd. trades at a P/E of 58.2 (premium valuation) with solid ROE of 11.9%. 3Y revenue CAGR of 14.7% highlights clear growth momentum.

Ask for details

Company Overview

Nibec Co., Ltd. is a biotechnology company primarily engaged in the research, development, and manufacturing of innovative biomaterials and healthcare solutions. The company's core focus is on the creation of peptide and biomaterial-based technologies tailored for the dental and medical industries. Nibec's groundbreaking research into peptides has led to the development of advanced dental adhesives and bone graft materials that increase the success rate of dental implants and surgeries, thereby impacting the dental healthcare sector significantly. Furthermore, Nibec contributes to the pharmaceutical industry with its development of peptide-based drugs that target various health conditions. The firm is known for its commitment to enhancing life quality through cutting-edge research and application of biomaterials. As part of the broader healthcare and materials sciences market, Nibec plays a vital role in driving innovations that have a lasting impact on medical treatments and patient care, underscoring its importance in the biotechnology and medical sectors.

CEO정종평
SectorHealthcare
IndustryBiotechnology
Employees96

Company Statistics

FY 2025

Profile

₩269,985,083,750Market Cap
₩32,718,793,370Revenue
11.37MShares Out
96Employees

Margins

63.52%Gross
26.83%EBITDA
15.36%Operating
14.10%Pre-Tax
14.19%Net

Valuation

58.16P/E
5.89P/B
8.25EV/Sales
29.39EV/EBITDA
493.63P/FCF

Growth (CAGR)

14.72%Rev 3Yr
38.77%Rev 5Yr
98.18%Op Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

7.40%ROA
11.89%ROE
8.16%ROIC

Financial Health

₩22,050,347,890Cash & Cash Equivalents
₩-4,871,241,200Net Debt
37.49%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Nibec Co., Ltd. (ticker: 138610) is a company listed on KRX in the Healthcare sector (Biotechnology). It has approximately 96 employees. Market cap is $270.0B.

The current price is ₩23,750 with a P/E ratio of 58.16x and P/B of 5.89x.

ROE is 11.89% and operating margin is 15.36%. Annual revenue is $32.7B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Nibec Co., Ltd. (Healthcare) Stock Forecast & Analysis ₩23,750 | Alpha Lenz